Gastroenterology
Latest news
416 articles · 20 / page
Vedolizumab Is Safer and More Effective When Used Early in Crohn’s Disease: Results from the Phase 4 LOVE‑CD Cohort
The LOVE‑CD phase 4 cohort shows vedolizumab yields higher sustained clinical and endoscopic remission and fewer serious adverse events when given early in Crohn’s disease versus later-stage, previously biologic‑exposed disease.
Etrasimod Shows Robust Induction and Maintenance Efficacy in East Asian Patients with Moderate–Severe Ulcerative Colitis
A phase 3 randomized trial in East Asia found oral etrasimod 2 mg superior to placebo for induction and maintenance of clinical remission in moderate–severe ulcerative colitis, with manageable safety and notable ALT elevations.
Tackling Fatigue in Primary Biliary Cholangitis: Key Recommendations from the European Reference Network Position Paper
A clear, practical summary of the 2025 ERN position paper on fatigue in primary biliary cholangitis (PBC) — epidemiology, assessment, the ASK‑MEASURE‑TREAT algorithm, and research priorities.
Cutting the Curve: Consensus Strategies to Reduce Alcohol‑Associated Liver Disease in the Population
A concise synthesis of a 2025 multistakeholder Lancet workshop consensus on population and clinical strategies to prevent, detect, and manage alcohol‑associated liver disease.
Phosphatidylethanol Reveals Substantial Underestimation of Alcohol Intake in Patients at Risk of Steatotic Liver Disease
A large prospective cohort shows phosphatidylethanol (PEth) correlates with self-reported alcohol intake but identifies frequent under-reporting; adding PEth to diagnostic pathways could improve subclassification of steatotic liver disease
Where Are People with Chronic Hepatitis B Lost? Global review shows major gaps after diagnosis — especially outside specialist care
A global systematic review (110 cohorts, 50 countries) found substantial attrition across the hepatitis B care cascade: low rates of treatment eligibility assessment and antiviral initiation in primary/community models, poor retention parti
Does AI Make Endoscopists Lazy? New Multicentre Data Show Reduced Adenoma Detection After AI Exposure
A multicentre observational study reports a 6% absolute fall in adenoma detection rate for non‑AI colonoscopies after clinicians were exposed to AI-assisted polyp detection—raising concerns about endoscopist deskilling and the need for safe
Peripheral blood DNA methylation signatures show promise for predicting response to vedolizumab and ustekinumab in Crohn’s disease — EPIC‑CD findings
An epigenome-wide study (EPIC‑CD) identified peripheral blood DNA methylation panels that predicted response to vedolizumab and ustekinumab (validated AUC 0.75 each) but failed to predict adalimumab response. Models worked best in biologic‑
Endoscopic Scoring After Crohn’s Surgery: Which Indices Reliably Detect Recurrence? Lessons from the PREVENT Trial Analysis
A blinded central-reader analysis of PREVENT ileocolonoscopy videos shows Rutgeerts, modified Rutgeerts, ileal REMIND, SES-CD and CDEIS are reliable and responsive in the neoterminal ileum, while performance is poorer at the anastomosis and
EASE‑CD: A Validated, Responsive Endoscopic Ulcer Activity Score That Advances Outcome Measurement in Crohn’s Disease
A new continuous index—EASE‑CD—focuses on ulcer presence, size, depth and proportion of ulcerated surface; it is reliable, responsive, and externally validated across two RCT datasets, offering a practical endoscopic endpoint for trials and
Cilofexor Did Not Prevent Fibrosis Progression in Non‑Cirrhotic Primary Sclerosing Cholangitis: Results from the PRIMIS Phase 3 Trial
The phase 3 PRIMIS trial found cilofexor 100 mg once daily did not reduce histological fibrosis progression at 96 weeks in non‑cirrhotic primary sclerosing cholangitis; pruritus was more frequent with cilofexor.
Linerixibat for Cholestatic Pruritus in Primary Biliary Cholangitis: Insights from the Phase 3 GLISTEN Trial and Related Studies
This review synthesizes evidence from the phase 3 GLISTEN trial and preceding studies on linerixibat, an ileal bile acid transporter inhibitor, demonstrating its efficacy and safety in reducing cholestatic pruritus in primary biliary cholan
What patients and clinicians want to know next: UK–Ireland research priorities for oesophageal and stomach cancers
A UK–Ireland partnership ranked the top research uncertainties for oesophagogastric cancers; priorities emphasize personalising multimodal treatment, nutrition and quality of life, and stronger patient-centred trial design to accelerate mea
Taipei Global Consensus II (2025): A Practical Guide to Helicobacter pylori Screening and Eradication for Gastric Cancer Prevention
An evidence-based synthesis of the 2025 Taipei Global Consensus II: 28 statements guiding H. pylori screening, eradication, surveillance and stewardship to reduce gastric cancer at individual and population levels.
Endoscopic Ultrasound–Guided Gastroenterostomy Outperforms Surgical Gastrojejunostomy for Malignant Gastric Outlet Obstruction: randomized trial shows faster recovery, shorter stay and lower costs
A multicentre randomized trial found EUS-guided gastroenterostomy (EUS-GE) superior to surgical gastrojejunostomy (SGJ) for malignant gastric outlet obstruction—improving oral intake, shortening hospital stay, enhancing quality of life and
ENDURO trial: EUS‑guided gastroenterostomy shortens time to oral intake and matches surgery for palliation of malignant gastric outlet obstruction
A randomized trial (ENDURO) found endoscopic ultrasound‑guided gastroenterostomy (EUS‑GE) enabled earlier resumption of solid food and was non‑inferior to surgical gastrojejunostomy for recurrent obstruction, supporting EUS‑GE as preferred
EUS-Guided Gastroenterostomy Beats Surgical Gastrojejunostomy for Malignant Gastric Outlet Obstruction: Randomised Trial Shows Faster Diet, Shorter Stay and Lower Costs
A multicentre randomized trial (NCT05548114) found endoscopic ultrasound‑guided gastroenterostomy (EUS‑GE) superior to surgical gastrojejunostomy (SGJ) for malignant gastric outlet obstruction, with faster return to solid diet, shorter hosp
CTNNA1 Truncating Variants Define a Moderate-Penetrance Hereditary Diffuse Gastric Cancer Spectrum — Implications for Testing, Surveillance and Risk Reduction
Large clinical and functional study shows CTNNA1-truncating variants cause loss of αE-catenin via nonsense-mediated decay, confer substantially elevated risks of diffuse gastric cancer and lobular breast cancer versus general population but
Microbiota, 3‑Hydroxyanthranilic Acid and Dopaminergic Signalling: A New Pathway Linking Obesity to Attention Deficits
A multi-cohort human study with mouse and Drosophila validation implicates gut microbes and the tryptophan metabolite 3‑hydroxyanthranilic acid in modulating attention in obesity, suggesting microbiota-directed interventions could improve c
Location Alone Shouldn’t Drive ESD: French Registry Finds Similar Submucosal Cancer Rates in Large Rectal and Colonic Non‑Pedunculated Polyps
A multicentre French ESD registry found that, after adjusting for size and morphology, large non‑pedunculated rectal polyps do not have higher rates of submucosal invasive cancer than equivalent colonic lesions; technical outcomes of ESD we
Browse by specialty
Open language-specific specialty feeds and department pages.